CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Do lifestyle choices affect university students’ grades February 2, 2026 Research uncovers intrinsic factors influencing CAR-T cell success October 29, 2024 Study highlights rising rates of tick-borne parasitic disease in the United States October 8, 2024